“Brodalumab in the Treatment of Moderate-to-Severe Psoriasis in Patients Refractory to Anti-Interleukin-17A Therapies: Evaluation of Secondary Endpoints”. 2021. SKIN The Journal of Cutaneous Medicine 5 (5): 524-29. https://doi.org/10.25251/skin.5.5.10.